HK1138181B - Immune modulators, compositions including immune modulators and use thereof - Google Patents

Description

Immunomodulator, composition containing immunomodulator and application thereof

Priority requirement

The present application claims priority from U.S. provisional application serial No. 60/848,348, filed 2006, 9, 29 and U.S. provisional patent application serial No. 11/855,944, filed 2007, 9, 14, the disclosures of both of which are incorporated herein by reference in their entirety.

Technical Field

The present invention relates to molecules that modulate (e.g., elicit, enhance, inhibit unwanted activity, etc.) cell-mediated immunity in a subject, including methods for producing and obtaining such molecules, formulations and compositions comprising such molecules, methods for evaluating the effectiveness of such molecules, and methods of use. More specifically, the present invention relates to small molecules, referred to herein as "nanofraction" molecules that modulate cell-mediated immunity.

Background

The ability of antibodies to provide and transfer immunity is well known and widely studied, as are the characteristics of antibodies and the mechanisms by which they are produced.

What is not clearly understood or widely studied is the role of transfer factors, which comprise a family of molecules with molecular weights of 3,500Da to 7,500Da, in mediating cell or T-cell mediated immunity. Over time, the understanding of the characteristics of transfer factors and their role in the immune system of an organism has improved and continues to improve by those skilled in the art.

While further research continues to elucidate the features and functions of various immune system components, a large proportion may not be well understood, or even ignore molecules that have an impact on the way immunity may be generated, maintained, transmitted and transferred, and on the effect of immunity on longevity.

DISCLOSURE OF THE INVENTION

The effectiveness of various molecules in modulating cell-mediated immunity has recently been characterized in a quantitative manner. Molecules that can directly or indirectly modulate cell-mediated immunity are known in the art and are referred to as "immunomodulators". One class of immunomodulators includes small or low molecular weight nanofraction (e.g., up to 3,000Da, up to 3,500Da, 250Da to 2,000Da, 2,000Da to 4,000Da) molecules that elicit, enhance, inhibit, or modulate a cell-mediated immune response. Because of the relatively small size or molecular weight of such immunomodulators, these are referred to herein as "nanofraction" immunomodulator and "nanofraction" molecules.

Nanofraction immune modulators can be obtained from a variety of different types of source animals. Examples of source animals include, but are not limited to, mammals (e.g., cows) and birds (e.g., chickens). Without limiting the scope of the invention, the nanofraction immune modulators may be obtained from colostrum or even milk produced by mammals. As another non-limiting example, the nanofraction immune modulators may be obtained from eggs laid by birds or any other type of animal. Other sources of colostrum, eggs, and nanofraction molecules are collectively referred to herein as "nanofraction sources.

The natural production of nanofraction immune modulators of a source animal may be enhanced by exposing the source animal to one or more antigens in an amount or concentration greater than the amount of antigen to which the source animal is typically exposed. For example, if a particular type of source animal, or even a particular source animal, is typically exposed to a particular amount or concentration of a given antigen in its usual environment, the production of immune modulators, including nanofraction molecules, of the source animal may be enhanced by exposing the source animal to an even higher amount (e.g., concentration) of the antigen (e.g., by vaccinating the source animal, by placing the source animal in an environment where a greater amount or concentration of the antigen is present, etc.). As another example, if a particular type of source animal, or even a particular source animal, is generally vaccinated with a given antigen, the source animal's production of one or more nanofraction immune modulators may be enhanced by improving the source animal's exposure to the antigen (e.g., by exposing the source animal to an improved concentration of the antigen, a more potent or virulent form of the antigen, etc.), although the nanofraction molecules themselves are not considered antigen-specific.

Known methods can be used to partially, mostly, or completely purify nanofraction immune modulatory molecules from other molecules present in the nanofraction-derived animal from which they were obtained, and optionally concentrate the nanofraction immune modulatory agent. Such methods include, but are not limited to, mechanical separation, phase separation (e.g., separation of aqueous and non-aqueous components from each other), precipitation, centrifugation, filtration (including microfiltration, using a molecular cut-off (MWCO) in the range of about 12,000Da to about 4,000Da, and nanofiltration, using a MWCO of less than about 4,000Da), dialysis, chromatography, and electrophoretic purification methods. Such methods may be performed alone or in any combination to produce a formulation in which one or more types of immunomodulators are present.

In one aspect, the invention includes at least partially purified, substantially purified (e.g., to the extent acceptable to those skilled in the relevant art), and fully purified immunomodulators. Thus, the present invention includes compositions comprising nanofraction molecules. In addition to nanofraction molecules, such compositions may include other components (e.g., transfer factors, antibodies, etc.) for supporting or modulating the immune system of a subject, as well as components that otherwise benefit the subject.

Methods of use or administration that include nanofraction molecules or compositions containing them alone or together with other immunomodulators are also within the scope of the present invention. Methods of use include administering one or more types of immunomodulatory agents (e.g., crude, partially purified, substantially purified, or fully purified forms, in a formulation, in a composition, etc.) to a subject (e.g., a human or any type of animal believed to benefit from the immunomodulatory effects provided by nanofraction molecules). The immunomodulator is administered to the subject in an amount (e.g., concentration) that improves the level of a particular administered immunomodulator type in the subject to a level higher than the normal amount for the subject. Without limiting the scope of this aspect of the invention, the subject may receive an amount of one or more immunomodulators that is clinically effective to cause the subject's immune system to elicit a cell-mediated immune response, or an amount that is effective to improve the subject's cell-mediated immune response.

In addition, assays and assay methods for evaluating the effectiveness of immunomodulators are within the scope of the present invention. For example, T-cell immune function assays can be used to evaluate the ability of potential immune modulators, alone or in combination with other molecules (e.g., antigens, mitogens (which induce mitosis or cell replication, etc.) to modulate one or more types of cells involved in cell-mediated immunity (e.g., the production of Adenosine Triphosphate (ATP)).

Other features and advantages will be apparent to those skilled in the art from consideration of the ensuing description and appended claims.

Brief Description of Drawings

In the drawings, FIGS. 1 through 4 are graphical representations of the results of various assays performed on compositions incorporating the teachings of the present invention.

Modes for carrying out the invention

Recently, small molecules of various molecular weight ranges have been found to be useful in modulating the activity of immune cells. The following examples set forth the work performed to investigate these conclusions.

Example 1

Fractions of various molecular weights are prepared from bovine colostrum and chicken eggs using known methods including phase separation, precipitation, filtration, microfiltration or nanofiltration and dialysis. The molecular weight fractions obtained from bovine colostrum were: 250Da to 2,000Da, 2,000Da to 4,000Da, 4,000Da to 8,000Da (which include transfer factors and include for comparison purposes) and 8,000Da to 12,000 Da. Similarly, 2,000Da to 4,000Da, 4,000Da to 8,000Da (which includes transfer factor and includes for comparison purposes) and 8,000Da to 12,000Da molecular weight fractions were prepared from egg yolk. The molecular weight fraction is then dried to a powder form (e.g., by spray drying, freeze drying, etc.).

Various assays were then performed using these preparations to evaluate the effect of the molecules in each fraction on the ability to modulate the cells that communicate cellular immunity (e.g., CD4+ T helper cells). Specifically, the types of assays disclosed in U.S. Pat. Nos. 5,773,232 and 6,630,316 and U.S. patent application publication 2005/0260563 were modified and used to evaluate the activity of the different molecular weight fractions from example 1 under various conditions. The above assays are used to evaluate Adenosine Triphosphate (ATP) production by immune cells (e.g., CD4+ T helper cells, CD3+ cells (which includes all T cells), etc.). The amount of ATP produced by the cells is measured in a manner known in the art (e.g., using the so-called "luciferin reaction", using a lumenometer).

Example 2

The first series of tests was performed using leukocytes from healthy individuals which included or expressed on their surface the so-called "CD 4" glycoprotein using Immunow produced by Cylex incorporated of Columbia, Maryland^TMAnd (4) testing. These leukocytes are also referred to as "CD 4 +" cells due to their CD4 glycoprotein expression. Expression of the CD4 glycoprotein distinguishes so-called "T helper" cells from other types of leukocytes, including other T cells.

ImmuKnow^TMThe components of the test kit are as follows: a standard 96-well "assay plate" comprising a removable eight-well plate; a "sample diluent" comprising growth medium and preservative; "stimulants" including phytohemagglutinin-L (PHA-L), a substance from legumes (e.g., red kidney beans) that is known to non-specifically stimulate mitosis (a process in which cells grow and divide into two new cells) and, therefore, stimulate the preparatory production of Adenosine Triphosphate (ATP) (i.e., mitogens) in leukocytes), diluted in growth medium and preservatives; "CD4 ", which is a magnetic sample purification bead covered with murine monoclonal anti-human CD4 antibody and carried by a buffered salt solution containing Bovine Serum Albumin (BSA) and a preservative; a "wash buffer" comprising a buffered salt solution comprising BSA; "lysis reagent", which includes a hypotonic alkaline solution containing a detergent, "calibration set", using0. ATP concentrations of 1, 10, 100 and 1,000 ng/ml; "luminescent reagent" comprising luciferin and luciferase in buffered solution that reacts with ATP to form an amount of light that is indicative of the amount of ATP that has been exposed to the luminescent reagent; and a "measurement plate," a 96-well with opaque borders (i.e., walls and base).

An eight-well plate of a 96-well assay plate, referred to as a "control" is used to provide controls, including four "unstimulated" (NS) control wells and four "stimulated" control wells.

An additional eight-well plate of 96-well assay plates, referred to as an "assay plate," is used for each sample to be assayed. Four wells of each sheet are designated as "unstimulated" wells, while the other four wells of each sheet are "stimulated" wells. Fifty microliters (50 μ l) of sample diluent was introduced into the four "unstimulated" wells of the pair, while 25 μ l of sample diluent was introduced into each "unstimulated" well of each assay plate. Twenty-five microliters (25 μ l) of stimulating agent were introduced into the four "stimulated" wells of the pair of photographs, and into the four "stimulated" wells of each assay plate.

In addition to the sample diluent or stimulant, a 25 μ l sample of one of the molecular fractions identified in example 1 was introduced into the eight wells of each assay plate. More specifically, each of the molecular weight fractions of example 1 was reconstituted in a sample diluent and diluted with a volume of sample diluent to provide three different concentrations when 25 μ l of sample was finally added to the wells, with amounts of 10 μ g, 100 μ g and 1,000 μ g of dry powder added to the wells, respectively.

A1: 3 (blood: "sample diluent") blood sample diluent was prepared, which had been gently stirred to evenly distribute its components, including leukocytes. Seventy-five microliters (75 μ l) of diluted blood was added to each well of each tablet. The contents of the wells are then mixed (e.g., by placing the plate on an oscillating plate for about 30 seconds) and then incubated at 37 ℃ and 5% CO₂Incubate at ambient for about 18 hours.

Once incubation is complete, the contents of the wells are washedMix again (e.g., by placing the plate on an oscillating plate for about three minutes). Thereafter, will includeMixing the solutions of the sample purification beads toThe sample purification beads are uniformly suspended within the liquid carrying them (e.g., using vortexing). As described above, in this embodimentThe sample purification beads included magnetic beads covered with murine monoclonal anti-human CD4 antibody. Fifty microliters (50. mu.l) of the carrierA solution of sample purification beads was added to each well of each plate.

The contents of each well are mixed again (e.g., on a vibrating plate for about 15 seconds) and then allowed to stand or incubate at room temperature for a period of about 15 minutes. The process of mixing and incubation is then repeated.The murine anti-human CD4 antibody on sample purified beads only bound leukocytes displaying the CD4 glycoprotein. During this incubation, CD4+ leukocytes including T helper cells pass throughImmobilization of murine monoclonal anti-human CD4 antibody on sample purification beads, or bindingSamples mouse monoclonal anti-human CD4 antibody on beads was purified.

After incubation, the contents of each well are mixed again (e.g., for about 15 seconds to about 30 seconds on a vibrating plate) to resuspendSample purification beads. According to Immunnow^TMThe protocol outlined in the accompanying specification was followed and the contents of each well were then introduced into a magnetic field (e.g., by placing each octawell plate in a disk available from Cylex). When receiving a magnetic field, willSample purification beads were poured into one side of each well where they were present. The remaining contents of the well are then removed (e.g., pipetted, etc.) and the beads and T helper cells are washed one or more times (e.g., three times with 200. mu.l of wash buffer each) to substantially purify them.

Two hundred microliters (200 μ l) of lysis reagent was then added to each well. After the contents of each well are removed from the magnetic field, the contents of each well (i.e.,sample purification beads, bead-attached cells, and lysis reagents) are mixed (e.g., on an oscillation plate for about five minutes). The cracking reagent destroysSample purification membranes of antibody-immobilized CD4+ cells on beads. In which ATP is released from the lysed cells.

Once cell lysis is complete, the contents of each well are subjected to a magnetic field, and the contents of each well are placed inThe sample purification beads were poured into one side of the well. Then 50. mu.l of sample was transferred from each well to the corresponding well of the measurement plate. In addition to transferring samples, several wells of a 96-well measurement plate were reserved for 50 μ l samples of various ATP concentrations of the calibration set solution.

One hundred fifty microliters (150 μ l) of luminescent reagent was then added to each well of the measurement plate, which included either the assay sample or a sample of the calibration set solution. The luminescence of each well was then measured. The measured luminescence of each well provides an indication of the amount of ATP present in that well. The amount of ATP present in each well then represents the amount of metabolic activity within the cells (i.e., CD4+ cells) from measuring the contents of each well of the plate. In samples produced with non-specific stimulation with PHA, relatively high levels of ATP are expected. Addition of an immunomodulator (e.g., from one of the fractions identified in example 1) will improve or reduce or modulate metabolic activity in CD4+ cells non-specifically stimulated by PHA.

The results of this assay are set forth in the following table, with the numbers shown representing the average amount of ATP produced by the leukocytes of each subset:

TABLE 1

Sample (I)		Control	10 ug/well	100 ug/well	1000. mu.g/well
						Colostrum fraction of 250Da to 2,000Da	Unstimulated (NS)	14	52	50	37
	Stimulation with PHA	388	336	253	127
							Reduced PHA stimulation%		13.4	34.8	67.3
Colostrum fraction of 2,000Da to 4,000Da	NS	14	52	62	42
							Stimulation with PHA	388	388	377	339
	Reduced PHA stimulation%		0	2.8	12.6
						Colostrum fraction of 4,000Da to 8,000Da	NS	14	69	50	46
	Stimulation with PHA	388	378	250	207
							Reduced PHA stimulation%		2.6	35.6	46.6
8,000Da to 12,000Da colostrum fraction	NS	14	49	45	39
							Stimulation with PHA	388	337	237	181
	Reduced PHA stimulation%		13.1	38.9	53.4
						2,000Da to 4,000Da egg fraction	NS	14	49	33	44
	Stimulation with PHA	388	228	161	148
							Reduced PHA stimulation%		41.2	58.5	61.9
4,000Da to 8,000Da egg fractions (including TF)	NS	14	54	47	44
							Stimulation with PHA	388	354	230	158
	Reduced PHA stimulation%		8.8	40.7	59.3

These data indicate that in a non-stimulated assay, in which the cells were not exposed to PHA, the 4,000Da to 8,000Da molecular weight fractions (from colostrum and egg), both known to contain transfer factors, stimulated additional metabolic activity in CD4+ leukocytes. These data demonstrate the ability of transfer factors to upregulate cell-mediated immunity.

In contrast, 4,000Da to 8,000Da colostrum and egg fractions down-regulate the non-specific ability of PHA to stimulate metabolic activity in CD4+ cells. Since PHA is an artificial, non-specific stimulant, down-regulation of its activity by transfer factors involved in cell-mediated immunity is not surprising. It is believed and previous studies have shown that transfer factors help to balance and even focus on immune activity caused by T-cells (e.g., by helping cells "remember" their original purpose, by reducing autoimmunity and related barriers, which improves activity against adverse entities, such as a subject infected with a microorganism (bacteria, virus, etc.)). The down-regulation of PHA-stimulating activity by T-cells appears to confirm this role of transfer factors in cell-mediated immunity.

Similar results were seen in various other molecular weight fractions that did not contain metastasis, including the 250Da to 2,000Da colostrum fraction (up and down), the 2,000Da to 4,000Da colostrum fraction (up) and the 2,000Da to 4,000Da egg fraction (up and down). The 8,000Da to 10,000Da colostrum fraction also causes an up-regulation of CD4+ leukocyte activity without PHA stimulation and a PHA-stimulated down-regulation of metabolic activity in CD4+ leukocytes.

These data confirm that immunomodulators other than transfer factors are present in at least the 250Da to 2,000Da colostrum fraction, the 2,000Da to 4,000Da colostrum fraction, and the 2,000Da to 4,000Da egg fraction. The immunomodulatory capacity of the "nanofraction molecules" present in each of these fractions was at least partially confirmed by the experiments shown in example 3.

Example 3

The second series of activity assays included leukocytes from healthy individuals presenting the CD3 glycoprotein (i.e., CD3+ cells), which are known to include all T-cells, including so-called "T memory" cells. In particular, T-cell memory using Cylex^TMAnd (4) measuring. T-cell memory of Cylex^TMThe protocol of the assay was very similar to that shown in example 2, with the following exceptions: mu.l of stimulating agent, including concanavalin A (ConA), instead of PHA, was introduced only into the "stimulated" wells of the photographs, while 25. mu.l of Cytomegalovirus (CMV) vaccine diluted 1: 10 was added to the "stimulated" wells of each assay plate (finally, dilution of each well was 1: 50); murine anti-human CD3 antibody was immobilized on the surface of magnetic beads (according to T-cell memory)^TMInstructions attached to the kit) to prepareSample purification beads; and prior to the initial incubation willThe sample purification beads are added to the blood sample, sample diluent, stimulating agent (if present) and sample fraction (if present).

Memory in T-cell^TMIn assays, antigens are used instead of mitogens (examples)Such as PHA) so that the ability of T memory cells to recognize specific antigens can be assessed. In particular, the intensity of light emitted from each well of the measurement plate is low because T memory cells constitute only a fraction of bound cellsThe antibody molecule of (1).

The results of these assays are listed in the following table, with the numbers shown representing the average amount of ATP produced by the leukocytes for each sample (and amount) determined:

TABLE 2

Sample (I)		Control	10μg	100μg	1000μg
						Colostrum fraction of 250Da to 2,000Da	Unstimulated (NS)	12	14	12	17
	Stimulation with CMV	316	468	338	345
							Increased stimulation of CMV%		48.1	7.0	9.2
2,000Da to 4,000Da primary milk fraction	NS	12	15	12	15
							Stimulation with CMV	316	501	503	440
	Increased stimulation of CMV%		58.5	59.1	39.2
						4,000Da to 8,000Da primary milk fraction	NS	12	22	16	19
	Stimulation with CMV	316	473	476	475
							Increased stimulation of CMV%		49.7	50.6	50.3
8,000Da to 12,000Da colostrum fraction	NS	12	14	18	26
							Stimulation with CMV	316	453	404	370
	Increased stimulation of CMV%		43.4	27.8	17.1
						2,000Da to 4,000Da egg fraction	NS	12	26	61	108
	Stimulation with CMV	316	305	349	350
							Increased stimulation of CMV%		-3.5	10.4	10.8
4,000Da to 8,000Da egg fractions (including TF)	NS	12	34	39	108
							Stimulation with CMV	316	310	280	381
	Increased stimulation of CMV%		-1.9	-11.4	20.6

The data obtained from the assays performed in this example 3 demonstrate that the three colostrum fractions containing non-transfer factor enhance the activity of the T memory cells assayed against CMV in the presence of antigen (i.e. specific stimulating agent, as opposed to non-specificity of mitogens such as ConA or PHA), to an extent comparable to (10 μ g samples of 250 to 2,000Da and 8,000Da to 12,000Da colostrum fractions) or exceeding (10 μ g and 100 μ g samples of 2,000Da to 4,000Da colostrum fractions) the capacity of colostrum fractions of similar size samples to 4,000Da containing transfer factor to improve the activity of the cells assayed when exposed to CMV.

Example 4

Another series of experiments was performed to determine whether nanofraction immunomodulatory molecules (i.e., immunomodulatory agents of the 2,000Da to 4,000Da colostrum fraction) or transfer factor-containing fractions (i.e., 4,000Da to 8,000Da colostrum fraction) are capable of modulating (e.g., enhancing) immune memory in a subject that has recently been exposed to high doses of a particular antigen. Specifically, blood samples were obtained from individuals who had been exposed to influenza virus causing systemic infection and had symptoms of influenza for four weeks.

The assay was performed in the manner described in example 3, using Cylex according to the description provided for the assay shown in example 3T-cell memory^TMThe assay replaced the CMV vaccine in example 3 with the influenza antigen in the form of a 1: 25 dilution of the influenza vaccine manufactured by Aventis Pasteur of Paris, France for the 2006-2007 influenza season (finally, the dilution per well was 1: 125).

The results of this assay are listed in the following table:

TABLE 3

Sample (I)		Control	10μg	100μg	1000μg
						Colostrum fraction of 2,000Da to 4,000Da	NS	4	10	3	4
	Stimulation with influenza antigens	827	1003	906	936
							ConA	694
	Stimulation of influenza antigens%		21.3	9.6	13.2
						Colostrum fraction (including TF) of 4,000Da to 8,000Da	NS	4	36	24	11
	Stimulation with influenza antigens	827	989	997	830
							ConA	694
	Stimulation of influenza antigens%		19.6	20.6	0.4

The results shown in table 3 (also graphically in figure 1) indicate that the activity of CD3+ memory T-cells was significantly improved when T memory cells of subjects who have recently been exposed to a particular antigen were exposed to that antigen, particularly in the presence of nanofraction molecules or transfer factors. In fact, relatively small amounts of nanofraction molecules and transfer factors caused an increase in T memory cell activity of about 20%. In fact, it can be seen that the immunomodulators of the 2,000Da to 4,000Da fraction are approximately as effective in modulating the activity of the cells being assayed as the transfer factor and any other molecules present in the 4,000Da to 8,000Da fraction.

The results from examples 1-4 indicate that immunomodulators having molecular weights in the range of 250Da to 2,000Da, 2,000Da to 4,000Da and 8,000Da to 12,000Da are effective in modulating the immune activity of various types of T cells. Thus, by administering such an immunomodulator or a formulation or composition comprising an immunomodulator to a subject, cell-mediated immunity in the subject can be modulated.

Based on these results, methods were developed to produce various dietary supplements (e.g., from (bovine) colostrum, (chicken) eggs, etc.) containing predetermined MWCO molecules. For example, and without limitation, a liquid formulation of a nanofraction immune modulator source from which at least large particles (e.g., colostrum/milk solids, eggshells, membranes, etc.) have been removed (e.g., by phase separation, filtration methods, etc.) may be forced through a filter having pores sized to provide a predetermined upper MWCO limit. By way of non-limiting example, a filter providing a molecular weight cut-off of about 3,000Da may be used. Alternatively, a dialysis process can be used which comprises the use of a dialysis membrane having pores which provide the desired MWCO. Use of such a method provides a "nanofraction" with the removal of larger molecules, including transfer factors, antibodies, and various other molecules having molecular weights in excess of about 3,000 Da. For example, colostrum, chicken and various powdered compositions are produced. The filtrate (i.e., the liquid portion that passes through the filter) can then be further processed by known techniques (e.g., freeze drying, spray drying, evaporation to form a more liquid, incorporation into a gel, etc.). The resulting "nanofraction product" can then be used alone or incorporated into other compositions.

It is believed that by including nanofraction molecules in a formulation that also includes transfer factor (and which also includes baseline levels (i.e., those levels already present in the source from which the transfer factor was obtained (e.g., colostrum, eggs, etc.), the resulting composition will down-regulate the desired activity caused by T-cells (e.g., autoimmunity and related disorders, etc.), while improving or up-regulating the desired T-cell activity, even in very small amounts.

TABLE 4 composition A

Composition (I)	Relative amounts (by weight)
		Bovine colostrum fraction, upper MWCO 10,000Da (spray drying)	68％
Bovine colostrum fraction, upper MWCO 3,000Da (nanometer fraction) (spray drying)	2％
		Egg yolk (spray drying)	30％

The compositions of table 4 may also be referred to as "immunomodulatory components". Such "immunomodulatory components" may consist essentially of a source of immunomodulators (including a source of nanofraction immunomodulators) or a mixture of immunomodulator-derived extracts, such as those listed in table 4, or it may include other components.

Likewise, compositions incorporating teachings of the present invention may consist essentially of "immunomodulatory components" as disclosed in table 4, or may include other components as shown in table 5.

TABLE 5 composition B

Composition (I)	Amount (one capsule for each part, one size)
		Composition A	150mg
Zinc (as monomethionine)	5mg
		CordyvantTMPatented polysaccharide complexes	440mg
IP-6 (inositol hexaphosphate)
		Soybean extract (phytosterol)
Cordyceps sinensis (7% cordycepic acid)
		Beta-glucan (from baker's yeast) (Saccharomyces cerevisiae)
Beta-glucan (from oats) (Avena sativa)
		Agaricus blazei Murill (Agaricus blazei) extract
Mannan (from aloe) (leaf)
		Olive leaf extract (Olea europaea)
Grifola frondosa (Grifola frondosa) (entire plant)
		Lentinus edodes (Lentinus edodes) (whole plant) (5: 1 extract)

The compositions according to the invention may be embodied as liquids (e.g. incorporating materials available from 4Life research, LC, Sandy, Utah)In a beverage), a powder (which may include other ingredients to provide a desired flavor, dissolution profile, etc.), a tablet (which additionally includes other ingredients, such as a binder (e.g., starch), etc.), a gel (to which gelatin or other ingredients are added), or in any other suitable form. It is to be understood that for purposes of this disclosure, other ingredients used in making these embodiments of the present compositions may only be considered optional and non-essential for the compositions for the purposes of this disclosure, unless the appended claims otherwise require.

Example 5

Blood was collected from individuals who had developed symptoms of herpes zoster (varicella zoster virus (VZV) infection) for about four weeks. Immunnow was then used in the manner described in example 2^TMThe assay was performed to assay blood, replacing the sample fractions of example 2 with: (a) a control that does not include an immunomodulator; (b) a colostrum fraction having an MWCO of about 3,000Da that has been spray dried; (c) adding transfer factorIt is currently available from 4Life Research and comprises bovine colostrum extract with an upper MWCO limit of about 10,000 Da; (d) the compositions in table 4, labeled "composition a"; and (e) the composition of table 5, labeled "composition B". Reconstituting each of (b) to (e) in Immunowo^TMThe incidental sample dilution was assayed and diluted to a concentration of 1mg/ml final per well concentration obtained once the blood sample and all other fluids were added to each well.

The results of these measurements are listed in the following table:

TABLE 6

	Control	Nanometer fraction	TF XF	Composition A	Composition B
						Unstimulated (NS)	26	35	77	47	19
Stimulation with PHA	220	234	150	140	27

These results are also shown in the graph of fig. 2.

Restated, these results were obtained at a time point (approximately four weeks after initial infection; i.e., during recovery), where reduced T helper (CD4+) cell activity was expected in the absence of stimulation, despite the large number of T helper cells still present in the subject's blood. In the absence of non-specific stimulant PHA, T helper cell activity was only slightly stimulated by the nanofraction, TF XF and composition a, and was not shown to be stimulated by composition B. However, nonspecific stimulation of T helper cells by PHA was significantly reduced by TF XF and composition a, and even to a greater extent by composition B, as would be expected from the results of example 2 listed in table 1.

Example 6

At an earlier time point (approximately one week after the onset of herpes zoster symptoms), T memory cells would be expected, although not present in large concentrations in the subject's blood due to the local nature of the VZV infection causing herpes zoster (i.e. relatively low VZV blood titers), would have recognized the VZV infection and be readily stimulated by the presence of VZV antigens. Thus, T-cell memory is performed^TMAssays to determine the effect of nanofractions, TF XF, composition a and composition B on T memory cells from the blood of the same subjects as determined in example 5. Following the protocol shown in example 3, with the following exceptions: instead of the CMV vaccine, a VZV vaccine was used, which had been diluted 1: 10 (final dilution per well 1: 50); and the sample fractions of example 3 were replaced with the control and immunomodulator used in example 5, each immunomodulator was diluted to a final per well concentration of 100 μ g/ml.

The following table lists the results of the measurements:

TABLE 7

	Control	Nanometer fraction	TF XF	Composition A	Composition B
						Unstimulated (NS)	1	2	13	27	51
Stimulated by VZV	1	5	30	32	69
						Stimulated by ConA	288

This data is also shown graphically in figure 3.

As expected, T memory cells stimulated the activity of transfer factors present in TF XF. The addition of a small amount of additional nanofraction molecules to the transfer factor significantly improved the activity of the T memory cells, both with and without additional VZV stimulation. Thus, the results of examples 5 and 6 demonstrate that adding additional nanofraction molecules to a formulation that also contains transfer factor, even in very small amounts, will down-regulate unwanted T-cell induced activity (e.g., autoimmunity and related disorders, etc.) while improving or up-regulating the desired T-cell activity.

Example 7

In another study, it was conducted to determine the ability of various compositions, including compositions containing transfer factor and additional nanofraction molecules as shown in tables 4 and 5, to stimulate the activity of Natural Killer (NK) cells against the human erythroblastic leukemia cell line K-562, which is sensitive to NK cells. Thus, NK cells are also referred to herein as "effector cells", while K-562 cells are also referred to herein as "tumor cells" and "target cells". Specifically, an MTT assay technique is used in which yellow 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT) is reduced to purple formazan by a reductase in the active mitochondria of living cells. Just prior to cytotoxicity analysis, formazan will be lysedA solution of (e.g., dimethyl sulfoxide in dilute hydrochloric acid (HCl), Sodium Dodecyl Sulfate (SDS), etc.) is added to each well. The number of viable cells in the determined wells is then determined using spectrophotometry, in which the amount of light of a particular wavelength (wavelength in the range of about 500nm to about 600 nm) absorbed by the solution in each well is measured, relative to the number of viable cells in one or more control wells to which no composition is added.

The compositions evaluated included transfer factor Advanced^TMAvailable from 4Life Research; transfer factor plusAdvanced^TMAlso available from 4Life Research; composition a comprising transfer factor and an improved amount of nanofraction molecules; composition B, which contains transfer factor, elevated amounts of nanofraction molecules and other ingredients thought to enhance immune system activity; nanofraction molecules from bovine colostrum; nano-fraction molecules from chicken eggs; and interleukin-2 (IL-2), available under the tradename Proleukin from Chiron of the Netherlands, which is known to recruit NK cells to fight cancer cells.

Blood was obtained from five healthy donors. The leukocytes are separated from the other components of the blood using known methods. Using known density gradient centrifugation techniques (e.g., using a technique available from Sigma-Aldrich Corporation of st. louis, Missouri)Density gradient) to isolate monocytes, including NK cells, from other types of leukocytes. Monocytes were introduced into RPMI 1640 growth medium containing 10% Fetal Calf Serum (FCS). Equal volumes of this mixture, including a concentration of about 60,000 leukocytes in 100 μ l of medium, were introduced into different wells of a standard 96-well plate. Reconstituted samples of the composition containing transfer factor and/or nanofraction molecules identified above, each having a concentration of 0.100mg of powder in 1ml of sterile deionized water, were added to three different wells containing leukocytes and growth medium, for a total of eighteen wells. In addition, 1,000IU/ml IL-2 was introduced into three positive control wells containing monocyte growth medium. Three negative control wells contained only the monocyte growth medium mixture and no immunomodulator. Three negative control wells containing only effector cells also contained only the monocyte growth medium mixture, while three negative control wells containing only target cells contained only 100. mu.l of growth medium.

At 5% CO₂Monocytes were incubated with the respective immunomodulatory compositions (except three negative control wells) for 48 hours in the presence at a temperature of 37 ℃ and humidity of 100%.

After incubation, approximately 30,000K-562 cells were introduced into each well containing monocytes and growth medium, except for three negative control wells with only effector cells. At 5% CO₂The mixture in the 96-well plate and the wells was incubated for another 48 hours at a temperature of 37 ℃ and a humidity of 100% in the presence.

MTT solutions were prepared according to known standard techniques, with 5mg MTT/ml Henk's salt solution. Twenty microliters (20 μ l) of MTT solution was introduced into each well of a 96-well plate containing monocyte-growth medium-tumor cells. Then at 5% CO₂The plate and its contents were incubated again in the presence at a temperature of 37 ℃ and a humidity of 100%, this time about four hours.

After this final incubation, the 96-well plates were centrifuged at about 1,500rpm for about five minutes. Thereafter, the supernatant (liquid) was removed from each well, and 150. mu.l of dimethyl sulfoxide (DMSO) was introduced into each well containing monocytes and tumor cells. The optical density of each cell-containing well was then measured using a spectrophotometer at a wavelength of 540 nm. The measured optical density was then used to determine the cytotoxicity index (%) of NK cells activated by each assay substance (CI (%)), using the following equation:

CI(％)＝[1-(OD_e+t-OD_e)/OD_t]×100，

wherein OD_e+tIs the optical density of each assay well corresponding to the assay composition, including the IL-2, OD of the positive control_eIs the average optical density, OD, of three negative control wells containing only effector cells_tIs the average optical density of three negative control cells containing only target cells. CI (%) represents the percentage of target cells that have been killed by NK cells in each well that also contained the assay modulating composition. The results are presented in the following table:

TABLE 8

These data, also shown in the graph of fig. 4, indicate that compositions containing nanofraction molecules, particularly those from bovine colostrum, are approximately as effective as IL-2 or more effective than IL-2 in eliciting NK cell activity against K-562 tumor cells, while compositions containing transfer factors from colostrum and eggs and nanofraction molecules from colostrum (i.e., composition a and composition B) activate NK cells more effectively than compositions without nanofraction molecules.

By adding as little as 2% by weight of more nanofraction molecules to the composition containing transfer factor, the nanofraction molecules can be stimulated by non-specific components of the cell-mediated portion of the subject's immune system (e.g., NK cells), complementing the ability of transfer factor to elicit activity by antigen-specific components of the cell-mediated portion of the subject's immune system.

When considered together, the results of examples 5 to 7 demonstrate that transfer factors regulate and prime (prime) T helper cells, which enable the subject's immune system to respond more rapidly and efficiently to pathogens and other adverse entities. Furthermore, examples 5 to 7 demonstrate that transfer factors can enhance the activity of T memory cells.

Examples 5 to 7 also show that the addition of additional nanofraction immune modulatory molecules to a composition containing transfer factor can enhance and improve the immune modulation of transfer factor and existing compositions containing transfer factor (e.g., immune modulation of T helper cells, T memory cells, and NK cells).

Methods of modulating cell-mediated immunity in a subject include administering (e.g., enterally, parenterally, etc.) a composition comprising nanofraction molecules to the subject. The nanofraction molecules can be administered alone, or as part of a composition consisting essentially of nanofraction molecules, or can be administered with a composition containing transfer factor (e.g., a composition listed in table 4 or table 5). Administration may be on a regular basis in an effort to maintain the overall balance of cell-mediated immunity in the subject, or in response to infection, autoimmune disorders, tissue transplantation, or other conditions that affect (activate or inhibit) cell-mediated immunity in the subject.

It is believed that administration of a composition containing nanofraction immune modulatory molecules in accordance with the teachings of the present invention modulates cell-mediated immune activity based on physiological needs. For example, adverse cell-mediated immune activity (e.g., autoimmunity, etc.) may be reduced. As another example, the ability of T cells to remove adverse pathogens and other adverse entities such as cancer cells and other abnormal or mutant cells in a subject (e.g., by activating T helper (CD4+) cells, which subsequently activate Natural Killer (NK) cells, by capacitating T memory cells with improved antigen-specific immunity) may also be concentrated and enhanced, particularly when the transfer factor is administered with an additional amount of nanofraction immune modulator molecules.

While the foregoing description contains many specifics, these should not be construed as limitations on the scope of the invention, but merely as providing illustrations of some of the presently preferred embodiments of this invention. As such, other embodiments of the invention may be devised which do not depart from the spirit and scope of the present invention. Features from different embodiments may be used in combination. Accordingly, the scope of the invention is indicated and limited only by the appended claims and their legal equivalents, rather than by the foregoing description. It is therefore intended to include all such additions, deletions and modifications to the invention as disclosed herein which fall within the meaning and scope of the claims.

Claims (12)

1. A composition for improving immune function comprising:

an immunomodulatory component, consisting of:

a first fraction consisting of a first fraction of bovine colostrum with an upper molecular weight cut-off of 10,000 Da;

a second fraction consisting of a second fraction of bovine colostrum, the upper molecular weight cut-off of the second fraction removing large particles, antibodies and transfer factors; and

egg, egg yolk or egg fractions.

2. The composition of claim 1, wherein the second portion comprises at least two percent by weight of the immunomodulatory composition.

3. The composition of claim 2, wherein:

the first portion comprises 68% by weight of the immunomodulatory composition; and

the egg or yolk accounts for 30% of the weight of the immunoregulatory component.

4. The composition of any of claims 1-3, wherein the upper molecular weight cutoff of the second fraction is 3,000D.

5. A composition for improving immune function comprising:

an immunomodulatory component consisting of:

a powdered bovine colostrum extract having an upper molecular weight cut-off of 10,000 Da;

a powdered bovine colostrum extract with upper limit molecular weight cut off to remove large particles, antibodies and transfer factors; and

powdered egg yolk.

6. The composition of claim 5, wherein the powdered bovine colostrum extract with the upper molecular weight cut off excluding large particles, antibodies, and transfer factors comprises at least two percent by weight of the immunomodulatory composition.

7. The composition of claim 6, wherein:

the bovine colostrum extract in powder form with an upper molecular weight cut-off of 10,000Da represents 68% by weight of the immunomodulating component;

the powder bovine colostrum extract with upper limit molecular weight cut-off and removed large particles, antibody and transfer factor accounts for 2% of the weight of the immunoregulatory component; and

the powdery egg yolk accounts for 30% of the weight of the immunoregulatory component.

8. The composition of any one of claims 5-7, wherein the powdered bovine colostrum extract, with the upper molecular weight cut off excluding large particles, antibodies and transfer factors, has an upper molecular weight cut off of 3,000D.

9. An immunomodulator for use in improving immune function, consisting of a fraction of bovine colostrum having an upper molecular weight cut-off that removes large particles, antibodies and transfer factors.

10. The immunomodulator of claim 9, wherein the upper molecular weight cutoff is 3,000D.

11. An immunomodulator according to claim 9, wherein the fraction is a colostrum fraction from 250D to 2500D.

12. Use of a composition according to any one of claims 1 to 8 or an immunomodulatory agent according to any one of claims 9 to 11 in the manufacture of a medicament for modulating the immune system of a subject.